209 filings
8-K
MCRB
Seres Therapeutics Inc
23 Apr 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:00am
8-K
MCRB
Seres Therapeutics Inc
8 Apr 24
Amendments to Articles of Incorporation or Bylaws
4:30pm
DEF 14A
MCRB
Seres Therapeutics Inc
Definitive proxy
5 Mar 24
10:18am
S-8
MCRB
Seres Therapeutics Inc
5 Mar 24
Registration of securities for employees
10:13am
10-K
2023 FY
MCRB
Seres Therapeutics Inc
Annual report
5 Mar 24
10:01am
8-K
cjrlnbb6ur
5 Mar 24
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
7:05am
8-K
k4yqlvqxqzjop3uc4u6
26 Feb 24
Seres Therapeutics Announces the Appointment of Marella Thorell As Chief Financial Officer and the Retirement of David Arkowitz
7:06am
8-K
u079rfzk llo21hh72l
30 Jan 24
Other Events
4:01pm
8-K
jhywftvy
10 Jan 24
Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155
7:00am
8-K
fc6rn1df1qwoou hp
9 Jan 24
Regulation FD Disclosure
7:05am
8-K
vp1 x7fepve1ah7
2 Jan 24
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
glzh7g5
2 Nov 23
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million
7:05am
8-K
lbsc6syap moqw4g
4 Oct 23
Departure of Directors or Certain Officers
7:00am
EFFECT
p36g1bz7maqci 6x
16 Aug 23
Notice of effectiveness
12:15am
UPLOAD
kzsjiujh93no 05fnd
11 Aug 23
Letter from SEC
12:00am
CORRESP
lo6r3
11 Aug 23
Correspondence with SEC
12:00am